A Feasibility Study of Increasing Magnesium Levels by Supplementation for Endocrine Related Cognitive Problems in Breast Cancer

niversity of Auckland0 个研究点目标入组 50 人开始时间: 2016年1月5日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•1. Women 18 years or older with early breast cancer on adjuvant endocrine therapy for at least 6 months.
•2. Receiving either tamoxifen or an aromatase inhibitor.
•3. Able to provide written informed consent in English (NB: The NIH Toolbox is only available in English).

•1. Evidence of metastatic disease
•3.Abnormal renal function defined as a serum creatinine of >1.5 x upper limit of normal.
•4.Abnormal hepatic function defined as a bilirubin of >1.5 x the upper limit of normal, except in Gilbert’s Syndrome, or ALT or ALP >2.5 x the upper limit of normal.
•5.Inadequate haematological function defined as haemoglobin < 100g/L or neutrophil count < 1.5 x E+9/L or platelet count < 120 x E+9/L
•6.Inflammatory bowel disease or other bowel disorder that causes ongoing diarrhoea.
•7.Any known cause of hypomagnesaemia, including: current treatment with loop diuretics, e.g. frusemide or thiazide; cyclosporine; amphotericin B; pentamidine; aminoglycosides; EGFR antagonists, e.g. cetuximab; past treatment with cisplatin; hypercalcaemia; uncontrolled diabetes; excess alcohol consumption; known familial magnesium wasting syndrome.
•8.A major psychiatric disorder and/or heavy alcohol, or illicit drug consumption, a history of traumatic brain injury or any condition unrelated to breast cancer treatment known to affect cognitive function.
•9.Receiving antidepressants, sedatives such as some antihistamines or gabapentin.
•10.Women who have been taking magnesium supplement within the last one month.

发起方

niversity of Auckland